EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Rational design of novel Plasmodium falciparum glutamyl-tRNA synthetase inhibitors for the development of next-generation antimalarial drugs

Wesam Nofal iD

PLOS One · 04.12.2025 · 20 (12) · e0334429

DOI: 10.1371/journal.pone.0334429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, online erschienen am 04.12.2025. Verfasst von Wesam Nofal. Beteiligte Einrichtung: Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Northern Border University, Arar, Kingdom of Saudi Arabia. Hauptthemen laut MEDLINE: Plasmodium falciparum, Antimalarials, Enzyme Inhibitors, Drug Design. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 74 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Northern Borders University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

A major obstacle in treating malaria is the emergence of antimalarial drug resistance. The aminoacyl-tRNA synthetases (aaRSs), which are essential enzymes for protein synthesis, have been identified as potential targets for the discovery of anti-parasitic drugs. Of these, Glutamyl-tRNA synthetase (GluRS) is a crucial aaRS enzyme in Plasmodium falciparum and is a vital therapeutic target. In this study, potential GluRS inhibitors are reported from the Medicinal Fungi Secondary Metabolites and Therapeutics (MeFSAT) chemical library using structure based virtual screening via PyRx v0.8. To evaluate the stability of top hit protein-inhibitor complexes, molecular dynamics simulations (time period, 100 ns) were performed from an initial batch of 1,830 compounds. The two shortlisted compounds, MSID000152 and MSID000974, showed the strongest negative binding affinities of −10.4 kcal/mol and −10.1 kcal/mol, respectively. For comparative analysis, Chloroquine was used as a control to validate the screening results. The dynamics of both complexes showed stable structure, with mean RMSD of 3.94 Å for MSID000152, 2.35 Å for MSID000974, and 2.39 Å for chloroquine. The MSID000152 illustrated favorable MMPB/GBSA binding free energy. Taken together, the study highlights MSID000152 and MSID000974 as promising antimalarial lead compounds for additional in vitro and in vivo investigations.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Plasmodium falciparumAntimalarialsEnzyme InhibitorsDrug DesignMolecular Dynamics SimulationHumansMolecular Docking SimulationMalaria, Falciparum

Substanzen

AntimalarialsEnzyme Inhibitors

Autor:innen und Institutionen

  • Department of Medical Laboratory Technology, Faculty of Applied Medical Sciences, Northern Border University, Arar, Kingdom of Saudi Arabia.

ORCID-Profile: Wesam Nofal

Förderung

  • Northern Borders University

Zitieren

APA

Nofal, W. (2025). Rational design of novel Plasmodium falciparum glutamyl-tRNA synthetase inhibitors for the development of next-generation antimalarial drugs. PLOS One, 20(12), e0334429. https://doi.org/10.1371/journal.pone.0334429

Vancouver

Nofal W. Rational design of novel Plasmodium falciparum glutamyl-tRNA synthetase inhibitors for the development of next-generation antimalarial drugs. PLOS One. 2025;20(12):e0334429. doi:10.1371/journal.pone.0334429

BibTeX
@article{Nofal2025,
  author = {Nofal, Wesam},
  title = {Rational design of novel Plasmodium falciparum glutamyl-tRNA synthetase inhibitors for the development of next-generation antimalarial drugs},
  journal = {PLOS One},
  year = {2025},
  volume = {20},
  number = {12},
  pages = {e0334429},
  doi = {10.1371/journal.pone.0334429}
}
Kostenlos starten →